Clinical Trials Logo

Cardiovascular Diseases clinical trials

View clinical trials related to Cardiovascular Diseases.

Filter by:

NCT ID: NCT03200756 Completed - Clinical trials for Cardiovascular Diseases

Cardiac Rehabilitation and Sedentary Behavior

Rest-CR
Start date: June 20, 2017
Phase: N/A
Study type: Interventional

This trial randomizes patients who plan to attend cardiac rehabilitation to either a behavioral intervention to specifically reduce sedentary behavior or to usual care which exclusively focuses on increasing exercise.

NCT ID: NCT03197363 Enrolling by invitation - Obesity Clinical Trials

BiaƂystok PLUS - Polish Longitudinal University Study

Bialystok+
Start date: November 5, 2018
Phase:
Study type: Observational

The main goal of the study is to provide a unique multidimensional picture of the health of the population with simultaneous optimal standards of sampling, processing and storing of data and biomaterial that will allow discovering novel mechanisms in the development and progression of common civilization diseases. In the effect it will improve prevention, diagnosis and treatment.

NCT ID: NCT03196024 Completed - Clinical trials for Diabetes Mellitus, Type 2

Corazon de la Familia (Heart of the Family)

Start date: October 5, 2017
Phase: N/A
Study type: Interventional

The Corazón de la Familia study is a randomized controlled trial to examine the effects of a novel family-focused lifestyle modification intervention to reduce risk for type 2 diabetes and cardiovascular disease (CVD) among Hispanics/Latinos. Facilitated by community health workers, the family-focused intervention engages two members of a family in an educational program addressing lifestyle behaviors to support sustained engagement in healthy lifestyles among Hispanics with high risk for type 2 diabetes or CVD. In this study, we will conduct a randomized controlled trial using a 2-group design and compare the short-term and long-term impact of the family-focused active intervention to an individual-focused control condition on biological and behavioral type 2 diabetes and CVD risk factors. Furthermore, we will examine outcomes of participants in the family-focused intervention to determine how each family member's engagement in healthy lifestyle behaviors and level of support for the other family member's engagement in healthy lifestyle behaviors affects their own and their partner's outcomes.

NCT ID: NCT03194152 Completed - T2D Clinical Trials

Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population

Start date: October 24, 2017
Phase: N/A
Study type: Interventional

This is a 2 parallel-arm randomized controlled study with free-living subjects on self-selected diets. The objective of this study is to compare the effects of two servings of peanuts with an isocaloric matched refined carbohydrate snack food on glucose, lipids and lipoproteins and cardiovascular health risk factors, satiety and gut microbiota in 250 Chinese participants at risk for metabolic syndrome (overweight/obese, enlarged waist circumference, elevated LDL-cholesterol, prehypertension, and/or prediabetes). The investigators hypothesize that the inclusion of 2 serving of peanuts in the diet will decrease blood glucose, LDL-cholesterol, and improve satiety sanctification between meals and gut microbiota compared to the control group and baseline.

NCT ID: NCT03192410 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)

Start date: April 2002
Phase: N/A
Study type: Observational

The Alpha Omega Cohort is a prospective study of 4,837 state-of-the-art drug-treated Dutch patients aged 60-80 years who had a clinically diagnosed myocardial infarction up to 10 years before enrolment. During the first 40 months of follow-up, patients took part in an experimental study of low doses n-3 fatty acids (Alpha Omega Trial, ClinicalTrials.gov NCT00127452). At baseline (2002-2006), data on medical history, medication use, diet, lifestyle and other factors were collected by means of questionnaires. Patients were physically examined by trained research nurses and blood samples were obtained. Follow-up for vital status and cause-specific mortality is ongoing. The trial was approved by a central medical ethics committee (Haga Hospital, The Hague, The Netherlands) and all patients provided written informed consent.

NCT ID: NCT03191708 Completed - Clinical trials for Coronary Artery Disease

The FAVOR II China Study

Start date: June 13, 2017
Phase: N/A
Study type: Observational

Quantitative Flow Ratio (QFR) is a novel method for evaluating the functional significance of coronary stenosis. The purpose of the FAVOR II China study is to evaluate the diagnostic accuracy of on-line QFR with FFR as the reference standard. The secondary purpose is to compare the diagnostic accuracies between online QFR and online QCA, with FFR as the reference standard.

NCT ID: NCT03191630 Completed - Clinical trials for Cardiovascular Diseases

Increasing Activity Post-Kidney Transplant With SystemCHANGE

CHANGE
Start date: October 1, 2017
Phase: N/A
Study type: Interventional

Inactivity is a common problem among older kidney transplant recipients (KTRs) and is associated with their high incidence of obesity and cardiovascular problems which are the leading cause of death for KTRs. However, the combination of SystemCHANGE activity trackers holds promise for increasing physical activity of KTR patients post-surgery. This pilot study will incorporate Fitbit health trackers with an intervention of questions about influences to physical activity in a population of kidney transplant recipients who are at particularly high risk of cardiovascular disease and death.

NCT ID: NCT03191227 Completed - Obesity Clinical Trials

The Cork and Kerry Diabetes and Heart Disease Study (Phase II) Mitchelstown Cohort

Mitchelstown
Start date: April 2010
Phase: N/A
Study type: Observational [Patient Registry]

The aim of the Cork and Kerry Study Phase II (Mitchelstown cohort recruited 2010-11) is to provide an updated profile of glucose tolerance status, cardiovascular health and their related factors in an Irish adult general population sample and to compare the findings with those obtained during baseline assessment of Phase I of the Cork and Kerry study (1998) and the rescreen (2008).

NCT ID: NCT03190798 Withdrawn - Clinical trials for Cardiovascular Diseases

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Start date: September 1, 2017
Phase: Phase 4
Study type: Interventional

RESEARCH HYPOTHESIS - In subjects with T2DM and HF, effect of canagliflozin will be superior to placebo for the change from baseline in PCWP after a single dose (6 hours post-dose) and after 4 weeks. - Treatment with canagliflozin will be well tolerated over 4 weeks.

NCT ID: NCT03188705 Completed - Clinical trials for Coronary Artery Disease

CES1 Carriers in the PAPI Study

Start date: October 14, 2019
Phase: Phase 4
Study type: Interventional

This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396). The purpose of this investigation is to assess the impact of genetic variation in the carboxylesterase 1 (CES1) on response to clopidogrel as well as dual antiplatelet therapy (i.e. clopidogrel and aspirin), as assessed by ex vivo platelet aggregometry, in healthy Amish individuals. The investigators hypothesize that participants who carry alleles that modify the activity or expression of CES1 will have altered response to clopidogrel as well as dual antiplatelet therapy.